6/13/2011

Interim results of a midstage study indicate that blinatumomab, an investigational drug from Micromet, produced complete remission in nine of 12 patients whose acute lymphoblastic leukemia had relapsed after conventional treatment. The positive data could bring accelerated FDA approval, an analyst said.

Full Story:
Bloomberg

Related Summaries